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In this issue of Cancer Cell, Brenner et al. describe that the poly-(ADP) ribose polymerase (PARP) may
mediate ERG function and that PARP blockade has antitumor activity in ETS gene-rearranged prostate
cancer models. These data support the clinical evaluation of PARP inhibitors for treating ETS gene-
rearranged prostate cancers.The hormone dependence of prostate
cancer was described seven decades
ago. More recently, trials of drugs target-
ing continued androgen receptor (AR)
signaling have confirmed the critical role
of the AR in driving prostate cancer
across the entire spectrum of the disease
through to the fatal phenotype (Attard
et al., 2009a). However, despite improve-
ments in treatment, resistance to these
next-generation therapies invariably
develops. Novel treatment approaches
for prostate cancer, particularly treat-
ments sparing hormone function, remain
an unmet medical need.
The discovery of gene fusions that
result in hormone-regulated overexpres-
sion of oncogenes (Tomlins et al., 2005)
suggested that a main mechanism under-
lying the response to hormone treatment
was downregulation of the 30 gene fusion
partner. This is supported by preclinical
evidence that ERG knockdown in
AR-dependent cancer cells with a
TMPRSS2-ERG gene fusion inhibits cell
growth and invasion (Tomlins et al.,
2008), and by the re-expression of high
levels of ERG in ERG-rearranged, pro-
gressing, castration-resistant tumors
(Attard et al., 2009b). Although the pres-
ence of a TMPRSS2-ERG gene fusion
(the most common gene fusion type)
does not appear sufficient for prostate
cancer initiation, prostate cancer cells
with this rearranged gene may be ‘‘ad-
dicted’’ to it.
The discovery and development of
compounds targeting ERG (or the less
common ETS fusion proteins ETV1,
ETV4, or ETV5) signaling may be many
years from becoming reality. The identifi-
cation of proteins that interact with these
oncogenes, and are key to their function,and can be targeted by therapeutics in
clinical development is an attractive alter-
native approach. With this aim in mind,
Brenner and Ateeq (2011) have identified
a number of proteins with a high proba-
bility of interaction with ERG, including
as top hits the DNA-dependent protein
kinase (DNA-PKcs) complex of DNA
repair enzymes. An immediate appeal
of this discovery is the advanced stage
of the clinical development of drugs in-
hibiting Poly(ADP-Ribose) Polymerase
(PARP), a key DNA repair protein identi-
fied in these studies to interact with ERG
through a DNA-independent mechanism.
These data indicate that PARP1 is criti-
cally important to ETS protein function
and that PARP1 inhibitors may block
ETS-mediated transcription. Moreover,
these authors have shown that PARP
inhibitors have antitumor activity in ETS
gene-driven prostate cancer models.
Studies have previously shown that
potent PARP inhibitors such as olaparib
and MK4827 have significant and durable
antitumor activity in ovarian, breast, and
prostate cancer patients whose tumors
lack competent homologous recombina-
tion DNA repair, for example, due to
loss-of-function BRCA1 or BRCA2 muta-
tions (Fong et al., 2009; Yap et al., 2011).
Although BRCA loss-of-function muta-
tions may be relatively uncommon in
cancer cells in sporadic tumors, DNA
repair defects are probably much more
common. It has been postulated that
defective homologous recombination
(HR) DNA repair with proficient, lower
fidelity, nonhomologous end-joining
(NHEJ) DNA repair may be important in
accelerating the generation of DNA
double strand breaks (DSB) that result in
the ‘‘driver’’ rearrangements reported inCancer Celprostate cancer (Lin et al., 2009) (e.g.,
TMPRSS2-ERG). These DSBs may be a
result of ligand-bound androgen receptor
inducing topological changes to DNA, re-
sulting in genes like TMPRSS2 and ERG
being brought to the same transcription
factory loci, and activating topoisomerase
IIb to cleave DNA at specific androgen re-
sponse elements, which results in the
development of genomic rearrangements
by NHEJ (Haffner et al., 2010). The key
question is therefore what comes first:
defective HR DNA repair leading to ETS
gene rearrangements and PARP inhibitor
sensitivity, or ETS gene rearrangements
leading to PARP inhibitor sensitivity and
increased DNA DSB. It may be that both
of these explanations are correct.
Although further evidence is required to
prove that prostate cancers have an
underlying early defect in high fidelity HR
DNA repair, predisposing these cells to
acquiring ETS gene rearrangements, it is
clear that PARP inhibitors merit evaluation
in the treatment of ETS gene-rearranged
prostate cancers. Brenner and Ateeq
(2011) propose two mechanisms for
PARP inhibitors’ antitumor activity in
ETS gene-driven prostate cancers: 1) inhi-
bition of the PARP1-ETS complex that is
key to ERG-mediated invasion and cell
growth, and 2) synthetic lethality sec-
ondary to the accumulation of DNA DSB.
Further support for the clinical evaluation
of PARP inhibition in prostate cancer
comes from studies showing that PTEN
loss of function is associated with an
inability to elicit RAD51 foci in the pres-
ence of DNA strand breaks, an accumula-
tion of DNA DSB, and an increased sensi-
tivity to PARP inhibitors (Dedes et al.,
2010), as well as a poor prognosis (Reid
et al., 2010, Mendes-Pereira et al.,l 19, May 17, 2011 ª2011 Elsevier Inc. 573
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Previews2009). This could be of enormous clinical
significance due to the high prevalence
of PTEN loss of function in cancer,
including in prostate cancer with ERG re-
arrangements. Overall, therefore, the
appeal of these findings is obvious: ETS-
rearranged prostate cancer is very com-
mon and can be relatively easily identified
in tumor biopsies, urine (untreated
patients), or circulating tumor cells, allow-
ing patient selection for treatment (Attard
et al., 2009b). Interestingly, the in vivo
antitumor activity of PARP inhibition in
combination with the chemotherapy te-
mozolomide is greater than PARP inhibi-
tion alone in a preclinical model. A con-
cern of these results is, however, that
the significant antitumor activity observed
with temozolomide alone in this model is
not observed in patients. The synergism
between PARP inhibition and radio-
therapy has not been tested in these
models but, based on Brenner and
Ateeqs’ (2011) results, certainly merits
further evaluation in prostate cancer
patients. It is envisioned, however, that
single agent antitumor activity will be
important to the successful clinical devel-
opment of these agents.
PARP inhibitors are now undergoing
clinical evaluation in advanced sporadic
prostate cancer both as single agents
and in combination with chemotherapy.
It is therefore probable that the relevance
of Brenner and Ateeqs’ study will soon
become apparent. The careful design of
these trials will be critically important to
maximize the likelihood of their successful
evaluation: 1) patient selection based on
validated ETS gene breakapart fluores-
cence in situ hybridization (FISH) assays
is required; 2) evaluation of PTEN loss
in pretreatment tumor tissues is recom-
mended, although the degree of PTEN
reduction that would result in sensitivity574 Cancer Cell 19, May 17, 2011 ª2011 Elsto PARP inhibitors remains to be clarified;
3) evaluation of the impact of PARP inhib-
itors on gH2AX and RAD51 foci formation
in post-treatment cancer cells is also rec-
ommended in pharmacodynamic studies
as well as studies evaluating ETS gene
signaling; and 4) finally, it is possible that
PARP inhibitors will not result in imme-
diate falls in the circulating prostate
cancer tumor marker Prostate Specific
Antigen (PSA), since these agents
decrease ERG signaling without directly
impacting androgen receptor signaling.
Other endpoints evaluating the impact of
PARP inhibitors on radiologic disease
measurements, circulating tumor cells,
and symptoms are therefore necessary
to evaluate the antitumor activity of these
agents. Finally, Brenner and Ateeqs’
study also identifies other proteins that
significantly interact with ERG that could
represent therapeutic candidates, such
as Hsc70. Ultimately, if proven to be
effective, PARP inhibitors could be the
first of a generation of novel therapeutic
strategies that improve on or possibly
avoid the use of hormone therapy for
prostate cancer.
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